However, as a prognostic biomarker of disease aggressiveness, LEPR has also shown promise in several other cancers including prostate, endometrial and thyroid, indicating that its value in meningioma prognosis ought to be investigated further [53,54,55]. The gene discussed is LEPR; the disease is meningioma.